CompuMed regains OsteoGram rights

Article

Bone densitometry firm CompuMed's big plans for its OsteoGram bone mineral density testing technology may have hit a snag with the announcement that it has reacquired exclusive worldwide rights from the Bone Measurement Institute (BMI), a non-profit

Bone densitometry firm CompuMed's big plans for its OsteoGram bone mineral density testing technology may have hit a snag with the announcement that it has reacquired exclusive worldwide rights from the Bone Measurement Institute (BMI), a non-profit Merck subsidiary that had licensed the technology in 1995 (SCAN 9/13/95). Manhattan Beach, CA-based CompuMed reported that the OsteoGram Analysis Center generated a disappointingly small stream of royalty income.

BMI will return the rights to the OsteoGram technology at no cost to CompuMed, and will discontinue operating the OsteoGram Analysis Center on February 28, according to CompuMed. The company is considering distribution options such as new licensing revenues, as well as worldwide marketing of OsteoGram.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Diagnostic Imaging’s Weekly Scan: October 5 — October 11
Current Insights on Interoperability, Enterprise Imaging and AI Integration in Radiology
A Closer Look at the Mammo Enhance Heart Program: An Interview with Arthy Saravanan, MD
© 2025 MJH Life Sciences

All rights reserved.